

4 .		
AD		
ΔU		

GENETIC ENGINEERING OF CLOSTRIDIUM DIFFICILE TOXIN A VACCINE

ANNUAL REPORT

Lycurgus L. Muldrow Joe Johnson

August 16, 1990

Supported by

U. S. ARMY MEDICAL RESEARCH AND DEVELOPMENT COMMAND FORT DETRICK, FREDERICK, MARYLAND 21702-5012

Contract No. DAMD17-87-C-7135

Spelman College Atlanta, Georgia 30314



Approved for public release; distribution unlimited.

The finding in this report are not to be construed as an official Department of the Army position unless so designated by other authorized documents.

20030214090

00 9 9 99 98 5

			۲Ÿ											

SECURITY CLASSIFICATION OF THIS PAGE									
REPORT (OCUMENTATIO	N PAGE	Form Approved OMB No. 0704-0188						
1a. REPORT SECURITY CLASSIFICATION Unclassified		16. RESTRICTIVE MARKINGS							
2a. SECURITY CLASSIFICATION AUTHORITY		3. DISTRIBUTION/AVAILABILITY OF REPORT							
2b. DECLASSIFICATION/DOWNGRADING SCHEDU	LE	Approved for public release, distribution unlimited							
4. PERFORMING ORGANIZATION REPORT NUMBE	R(S)	S. MONITORING ORGANIZATION REPORT NUMBER(S)							
6a. NAME OF PERFORMING ORGANIZATION	6b. OFFICE SYMBOL	7a. NAME OF MONITORING ORGANIZATION							
Spelman College	(If applicable)								
6c. ADDRESS (City, State, and ZIP Code)		7b. ADORESS (Cit	y, State, and ZIP (ode)					
Atlanta, Georgia 30314									
84. NAME OF FUNDING/SPONSORING ORGANIZATION U.S. Army Medical	8b. OFFICE SYMBOL (If applicable)	9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER							
Research & Development Command	(ii applicable)	DAMD17-87-C-7135							
8c. ADDRESS (City, State, and ZIP Code)		10. SOURCE OF F							
Fort Detrick	,	PROGRAM ELEMENT NO.	PROJECT NO. 3M1	TASK NO.	ORK UNIT CESSION NO.				
Frederick, Maryland 20702-5012		62770A	62770A871	A/	A	348			
11. TITLE (Include Security Classification)									
(U) Genetic Engineering of <u>Clostridium</u> <u>difficile</u> Toxin A Vaccine									
Lycurgus L. Muldrow and Joe Jo	hnson								
13a. TYPE OF REPORT 13b. TIME CO Annual FROM6/15	VERED 10 6/14/90	14. DATE OF REPORT (Year, Month, Day) 15. PAGE COUNT 8/16/90 14							
16. SUPPLEMENTARY HOTATION			10, 50						
17. COSATI CODES	18 SUBJECT TERMS'(•	identify	by block nu	mber)			
FIELD GROUP SUB-GROUP	Clostridium	difficile Va	ccine,						
06 02	06 02 Recombinant DNA.								
19. ABSTRACT (Continue on reverse if necessary	and identify by block ne	imber)							
The long range goal of this project is to use <u>C. difficile</u> toxin A as a model to add technical information in the area of vaccine biotechnology using recombinant DNA techniques. This will be accomplished in part by predicting epitopes from the DNA sequence of toxin A, synthesizing DNA for these predicted regions, and testing their antigenic activity in expression vectors. Part of the toxin A gene has been cloned and sequenced. A total of twelve different epitopes have been predicted, synthesized, cloned into lambda gtll and tested for antigenicity. Alternative procedures for epitope mapping has been described and initiated.									
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT		21. ABSTRACT SEC		TION					
☐ UNCLASSIFIED/UNLIMITED ② SAME AS RI 228. NAME OF RESPONSIBLE INDIVIDUAL	PT. DTIC USERS	Unclassif 226 TELEPHONE (A		22c. Of	FFICE SYMBO	ગ			
Mary Frances Bostian		301-663-732	5		D-RMI-S				

SUMMARY

Recombinant DNA technology allows for an approach to subunit vaccine production that should provide advantages over existing techniques. Improvement of vaccine biotechnology in the area of recombinant DNA studies using Clostridium difficile toxin A as the model, is the major long range objective of this project. This will be accomplished in part by predicting epitopes from the DNA sequence of toxin A, synthesizing DNA for these predicted regions, and testing their antigenic activity in expression vectors. Twelve regions representing the highest Antigenic Index peaks were selected and DNA oligomers for these corresponding regions were synthesized (fig. 1). Additional bases were added to these fragments in order to generate an EcoRI site. These synthetic single strain oligomers were then annealed and ligated into lambdagt11 and subsequently tested positive for the generation of clear plaques using X-gal. The clones were then tested with antiserum against toxin A to assay for antigenicity. Under the immunobolt conditions tested, peptides produced by these cloned fragments did not react with toxin A antibodies.

The 12 epitopes predicted represent the most probable antigenic regions using the IBI and MESQ software. These predicted an tested regions may not have been antigenic due to a variety of reasons. First, parameters for prediction did not allow for the selection of the appropriate epitopes. Second, the antigenic sites tested may represent discontinuous epitopes which cannot be selected using the above described procedures. Third, the antigenic site(s) from this particular system could not be expressed in the lacZ gene of \(\lambda\gamma\text{t11}\). And finally, these AT rich DNA fragments were not stable in the \(\lambda\gamma\geta\text{t11}\) cloning system. Alternative procedures for epitope mapping has been described and initiated.

Acces	ssion For
DTIC Unant	GRANT G TAB nounced ification
By_Dist:	ribution/
Avai	llability Codes
p1=e	Avail and/or Special

FOREWORD

Citations of commercial organizations and trade names in this report do not constitute an official Department of the Army endorsement or approval of the products or services of these organizations.

The investigator(s) have abided by the National Institutes of Health Guidelines for Research Involving Recombinant DNA Molecules (April 1982) and the Administration Practices Supplements.

TABLE OF CONTENTS

	Page
Background	4
Materials and Methods	5
Results and Discussion	6
Conclusions	8
References	8
Figures	
Figure 1. Epitopes Predicted for the 300 bp of Toxin A Gene.	11
Figure 2. Southern hybridization of restriction digested C. difficile chromosomal DNA with [alpha- ²² P] dCTP labeled lambda cd19.	12
Figure 3. Toxin A DNA inserts digested from BlueScript hybrids. An 800 bp fragment was amplified from C. difficile strain 10463, and cloned	
into the Notl site of BlueScript.	13
Distribution List	14

BACKGROUND

Recombinant DNA technology allows for an approach to subunit vaccine production that should provide advantages over existing techniques. The major long range objective of this project is directed toward the improvement of vaccine biotechnology in the area of recombinant DNA studies using Clostridium difficile toxin A as the model. This was proposed to be accomplished by using a unique series of recombinant DNA techniques to map epitopes.

1. C. difficile Toxin A Literature Review

<u>C. difficile</u> was first described in 1935 (I), but has only been recognized as a clinically significant pathogen within the last twelve years. This toxin producing nosocomial pathogen (2,3,4,5,6) is the causative agent for the diarrheal syndrome termed antibiotic associated pseudomembranous colitis (PMC) (7,8,9,10). PMC is a disease of the lower gastrointestinal tract that can be histopathologically characterized by exudative plaques on the bowel mucosa. If left untreated it can be fatal. The etiology of PMC does not only depend on colonization of <u>C. difficile</u> toxin producing strains, but other factors affecting the gastrointestinal tract may initiate the disease state, such as surgery, cancer chemotherapy and most frequently antibiotic therapy (11,12,13,14,15).

Pathogenicity and cytotoxicity associated with PMC has been linked to production of two toxins, A (enterotoxin) and B (cytotoxin). There have been a number of publications describing biological characteristics of toxins A and B (16,17,18,19,20,21,22) and evidence has developed to indicate that toxins A and B work synergistically to cause PMC (23,24).

Toxin A is a large protein that has been demonstrated to elicit a hemorrhagic fluid response in the rabbit intestinal loop assay, cause fluid accumulation in the suckling mouse assay (25,26), exhibit cytotoxic activity on mammalian tissue culture cells (27), and bind to and agglutinate rabbit erythrocytes (28). The molecular weight of toxin A has been reported by several different groups, using non-denaturing gels and gel filtration, to be approximately 440,000 to 600,000 (29,30,31). Studies directed toward the molecular genetics or DNA of C. difficile toxin A have been appearing in the literature in increasing numbers in the last several years. The first paper published on cloning part of C. difficile toxin A was reported by our group (32). Since this publication several other studies have followed on cloning, expression in E. coli, and sequencing of toxin A (33,34,35,36,37). We have also recently submitted for publication data that demonstrates that toxic strains of C. difficile normally contain the genetic composition for toxin A and B simultaneously (38).

The objective of this project is to use toxin A of <u>C. difficile</u> in a unique series of molecular procedures for the prediction, identification and purification of antigenic sites, which may ultimately be used as a model system for the development of subunit vaccines. Recombinant DNA technology allows for an approach to subunit vaccine production that should provide advantages over existing techniques. Potential advantages of genetically engineered antigens for the preparation of vaccines are stability, purity, safety of preparation, price, lack of side effects and variety of serotypes.

A number of determinants coding for antigens have been cloned from viruses, bacteria, parasites and toxins, with the long range goal of producing better vaccines and improving molecular techniques for the development of vaccines. Improvement of vaccine biotechnology in the area of recombinant DNA research is the major long range objective of this project.

2. First and Second Year Accomplishments

A genomic library in lambda gt11 of <u>C</u>. <u>difficile</u> chromosomal DNA was screened using anti-toxin A which resulted in the identification of one stable positive clone, lambda cd19. The insert in lambda cd19 was demonstrated to be a 0.3 kb fragment by restriction digestion, and by hybridization of the clone to a chromosomal digest of <u>C</u>. <u>difficile</u>. Verification of the immunological identity of the isolated toxin A gene fragment in lambda cd19 was determined by affinity purifying toxin A antibodies specific for lambda cd19 gene product, and using these selected antibodies to probe a Western blot of purified toxin A. After further biological characterization of this clone it was determined that this fragment contains an important antigenic region. The DNA of this fragment has been sequenced, and the amino acid sequence deduced.

This 0.3 kb toxin A positive fragment was demonstrated by Southern blot analysis to hybridize to a 16 kb fragment from a HindIII digestion of C. difficile chromosomal DNA. In an attempt to isolate the entire toxin A gene, the 16 kb HindIII fragment was cloned by digesting C. difficile DNA with HindIII, and separating the DNA fragments in the range of 12 to 20 kb using high pressure liquid chromatography. These restriction fragments were then ligated into the HindIII site of λ2001, and packaged in E. coli NM539. The recombinant phages were screened with a synthetic 40 bp probe which was derived for the sequence of the 0.3 kb fragment. A λ2001 recombinant which hybridized to the toxin A probe has been isolated and partially characterized.

MATERIALS AND METHODS

1. DNA Sequence Analysis

Sequence analysis of DNA encoding for toxin A was determined using the Sanger chain-termination sequence procedure. Protocols and reagents from the Sequenase™ kit (United States Biochemical Corporation, Cleveland, Ohio) were used for dideoxy sequencing. <u>Taq</u> DNA polymerase was used for high temperature chain termination DNA sequencing to read through compressions (16). The TAQuence™ System from United States Biochemical Corporation was used.

2. DNA Synthesis

Oligodeoxynucleotides were synthesized using beta-cyanoethyl phosphoramidite chemistry in a MilliGen 7500 DNA synthesizer (17). Analysis and purification of oligonucleotides were preformed by either separating DNA by polyacrylamide gel electrophoresis in 15% to 20% gels (18), or by fractionating DNA on a trityl-specific

reverse phase Delta Pak C18 (Waters Inc.) high pressure liquid chromatography (HPLC) column.

3. Screening Predicted Epitopes

Synthetic DNA oligomer were cloned and screened using the lambda gt11 expression system of Young and Davis (40) with the following alterations. The oligomers that were ligated into the EcoRI site of lambda gt11 were packaged with PackageneTM (Promega Biotec, Madison, WI), and the recombinants were directly screened without amplification. Toxin A antigen-producing plaques were monitored for on nitrocellulose filters using a 1:200 dilution of E. coli-lambda gt11 absorbed anti-toxin A, and the Bio-Rad horseradish peroxidase-bound goat anti-rabbit IgG immunoblot kit (Richmond, CA).

4. Restriction Digestion, Cloning and Screening

Restriction endonucleaso digestion, and enzymatic manipulation of DNA for cloning were preformed as described by suppliers. Standard procedures that were used for isolation and manipulation of DNA for cloning are described in several molecular cloning manuals (19,20). Oligomers were radiolabeled by second strain synthesis using [alpha-³²P] dATP, and DNA hybridizations were performed as described earlier (15,19,20)

5. Computer Analysis

Nucleotide sequence data was analyzed by an IBM PC-XT computer with programs from International Biotechnologies, Inc., and a Digital Microvax computer using the data base and graphic programs of Cage/Gem (Battelle, Pacific Northwest Laboratories, Richland, Washington). Epitopes were predicted with the use of Pustell programs from International Biotechnologies, Inc., and the MSEQ programs from the University of Michigan.

6. PCR Amplification

Amplification of a 800 bp <u>C. difficile</u> toxin A gene fragment was carried out in a 50ul reaction volume containing 50ng of <u>C. difficile</u> DNA, 10mM Tris-HCl (pH 8.3), 50mM KCl, 1.5 mM MgCl₂, 2.5 units of Taq polymerase (Perkin Elmer, Norwalk, CT, USA), 200uM dNTP mix, and 0.2uM oligonucleotide primers. To ensure that all nuclease activity was destroyed, the reaction tube was heated for 5 minutes at 94°C prior to adding the Taq polymerase. Amplification was conducted for 37 cycles using a Perkin Elmer Cetus thermocyler (Norwalk, CT, USA). The cycle used to amplify the toxin A gene fragment consisted of denaturation at 94°C for 1 minute, annealing at 55°C for 1 minute, and extension at 65°C for 1 minute.

RESULTS AND DISCUSSION

During this past year a paper was published by C. H. Dove and coworkers (36)

on the entire <u>C</u>. <u>difficile</u> toxin A gene sequence. Based on the data published by this group, and data published by Von Ichil-Streiber's group (35) on overlapping toxin A DNA fragments which express antigenic sites, the DNA sequence of an 800 bp fragment has been identified which is though to have a major antigenic site. This 800 bp fragment has also been identified to contain the 300 bp fragment that we earlier reported on cloning (32). Using the above information epitopes were predicted using the Antigenic Index of the IBI Pustell software program.

The antigenic index prediction method described by Jameson and Wolf (39) generates values for surface accessibility parameters and combines these values with those obtained for regional backbone flexibility and predicted secondary structure. The linear surface contour profile generated from these calculations allows for predicting potential continuous epitopes. Twelve regions representing the highest Antigenic Index peaks were selected and DNA oligomers for these corresponding regions were synthesized (fig.1). Additional bases were added to these fragments in order to generate an EcoRI site. These synthetic single strain oligomers were then annealed and ligated into $\lambda gt11$ and subsequently tested positive for the generation of clear plaques using X-gal. The clones were then tested with antiserum against toxin A to assay for antigenicity. Under the immunoblot conditions tested peptides produced by these cloned fragments did not react with toxin A antibodies.

The 12 epitopes predicted represent the most probable antigenic regions using the IBI and MESQ software. These predicted an tested regions may not have been antigenic due to a variety of reasons. First, parameters for prediction did not allow for the selection of the appropriate epitopes. Second, the antigenic sites in this 800 bp fragment may represent discontinuous epitopes which cannot be selected using the above described procedures. Third, the antigenic site(s) from this particular system could not be expressed in the lacZ gene of $\lambda gt11$. And finally, these AT rich DNA fragments were not stable in the $\lambda gt11$ cloning system. This final explanation requires further discussion, because we have demonstrated that C. difficile toxin A DNA is highly unstable in lambda gtll.

From the original genomic library of C. difficile DNA, that was constructed in lambda gt11, approximately 35,000 plaques were screened for toxin A antigenproducing clones resulting in the original detection of 22 positive plaques. All but one of the identified positive plaques spontaneously lost the C. difficile inserts after plaque purification and amplification as indicated by immunologically testing for toxin A cloned antigens, and by reversion from clear to blue plaques. Lambda cd19 (the 300 bp Tagl clone) was the only recombinant plaque stable enough to allow for consistent immunological verification; however, as reported in the first annual progress report this clone lost one of the EcoRI cloning sites. It should be emphasized that this 300 bp Tagl fragment in lambda cd19 truly represents part of the toxin A gene. This has been verified by the numerous references that site the cloning of this fragment, and by the correlation of DNA hybridization patterns (33,34,35,36,41,42). However, the most convincing data that demonstrates the presence and location of this 300 bp cloned fragment comes from Dove's (36) DNA sequence of toxin A. The sequence data demonstrates that there is only one 300 bp Taql fragment within the toxin A gene. which is located within a 4.5 Fstl fragment, and a large HindIII fragment. Hybridization data published by our laboratory (32) demonstrated that [alpha-32P] labeled lambda

cd19 hybridized to a 4.5 kb fragment in a <u>Pst1</u> chromosomal digestion of <u>C</u>. <u>difficile</u>, and a 16 kb fragment in a <u>HindIII</u> digestion (fig. 2).

Despite the apparent stability of lambda cd19, it mutated soon after the initial characterization of this clone. It was determined that this clone had significantly mutated after it lost its ability to produce a peptide that would react with toxin A antiserum, and after the DNA sequenced was compared to Dove's sequence (36). Consequently, it can be predicted that one possibility that a positive epitope could not be identified using the predicted cloned oligomers in lambda gt11 was due to the fact that C. difficile DNA is not stable in lambda gt11.

Through personal communication with numerous other investigators that use the lambda gt11 cloning system, it has become apparent that AT rich DNA is not stable in lambda gt11. C. difficile DNA is 70% AT rich.

in order to fulfill the contractual arrangement to assist in the development of the area of vaccine biotechnology using recombinant DNA techniques, and C. difficile toxin A as the model, an alternative expression system is currently being studied. summary, fragments of C. difficile toxin A will be PCR amplified, subcloned into expression vectors, and tested for antigenicity using polyvalent antiserum made against toxin A. Upon identifying fragments that are immunoreactive, a series of overlapping exonuclease III generated deletion mutants will be produced and subcloned in the pATH3 expression vector (43,44). Selected N- and C-termini truncated fusion proteins generated from the deletion mutants will be tested by Western blotting to determine which mutants retained antigenic determinants. Upon narrowing down the region containing the epitope 'he exact sequence for the epitope will be identified by a series of different procedures including computer aided prediction, PCR site specific mutagenesis, and overlapping synthetic peptides. To date, the 800 bp fragment that has been identified to contain a major antigenic site has been PCR amplified with primers containing Not! sites, cloned (fig. 3), and expressed in the BlueScript expression system.

RECOMMENDATIONS AND CONCLUSIONS

One of the main objectives of this contract is to develop a system for testing epitopes using expression vectors such as lambda gt11, which includes reporting potential problems and solutions to these problems. From our experience of cloning toxin A, and as well as toxin B gene fragments in lambda gt11, and from personal communications with other investigators, we have identified a non-published common problems encountered when using this cloning system. AT rich DNA is not stable in lambda gt11. This cloning system as well as cosmids cloning systems should be avoided when the GC content of the DNA to be cloned is not similar to E. coli. By surveying the literature it appears that pBR322 derived vectors (including expression vectors) are more stable when using AT rich DNA.

REFERENCES


- 1. Hall, I.C., E. O'Toole, 1935. Am. J. Dis. Child. 44:390.
- 2. McFarland, L.V., M.E. Mulligan, R.Y.Y. Kwok, W.E. Stamm. 1989. N. Engl. J. Med. 320:204.
- 3. Campbell, R.R., D. Beere, G.K. Wilcock, E.M. Brown. 1988. Age Ageing. 17:333.
- 4. Cimino, J.J. 1989. N. Eng. J. Med. 321:190.

- 5. Eriksson, S., B. Aronsson. 1989. Scandinavian Journal of Infectious Diseases. 21:733.
- McFarland, L.V., W.E. Stam. 1988. Am. J. Epidemiol. 128:940.
- 7. Bartiett, J.S., T.W. Chang, N.S. Taylot, A.B. Onerdonk. 1979. Rev. Infect. Dis. 1:380.
- 8. Fekety, R. American Society of Microbiology. 276.
- 9. Medline, A., D.H. Skin, N.M. Medline, 1976. Human Pathol. 7:693.
- 10. Totten, M.A., J.A. Gregg, M.L. Freemont-Smith. 1978. Am. J. Gastroenterol. 69:311.
- 11. Treloar, A.J., L. Kaira. 1987. Lancet. 2:1279.
- 12. Binner, E.J., W.H. Tellman. 1970. Am Med. J. Gastroanterol. 34:55.
- 13. Gerard, M., N. Defresne, D. Daneau, P. Van Der Auwera, M. Delmee, A.M. Bourguignon, F. Meunier. 1988. Eur. J. Clin. Microbiol. Infect. Dis. 7:274.
- 14. Bartlett, J.G., A.B. Onerdonk, R.L. Cisneron, D.L. Kcoper. 1977. J. Infect. Dis. 136:701.
- 15. Satin, A.J., C.R. Harrison, K.C. Hancock, C.M. Zahn. 1989. Obstetrics and Gynecology 74:487.
- 16. Borriello, S.P., J.M. Ketley, J. Stephen. 1987. J. Med. Microbiol. 24:53.
- 17. Mitchell, T.J., J.M. Ketley, D.W. Burdon, D.C.A. Candy, J. Stephen. 1987. J. Med. Microbiol. 23:211.
- 18. Mitchell, T.J., J.M. Ketley, D.W. Burdon, D.C.A. Candy, J. Stephen. 1987. J. Med. Microbic¹. 23:205.
- 19. Mitchell, T.J., J.M. Ketley, D.W. Burdon, D.C.A. Candy, J. Stephen. 1987. J. Med. Microbiol. 23:199.
- 20. Ketley, J.M., T.J. Mitchell, D.C.A. Candy, D.W. burdon, J. Stephen. 1987. J. Med. Microbiol. 24:41.
- 21. Triadafilopoulos, G., C. Pothoulakis, M. O'Brien, J.T. LaMont. 1987. Gastroenterology. 93:273.
- 22. Lima, A.A.M., D.M. Lyerly, T.D. Wilkins, D.J. Innes, R.L. Guerrant. 1988. Infect. Immun. 56:582.
- 23. Lyerly, D.M., K.Ek. Saum, D.K. MacDonald, T.D. Wilkins. 1985 Infect. Immun. 47:349.
- 24. Rolfe, R.D., P. Kim. 1987. American Society Microbiology Meeting. Abstract No. B-222.
- 25. Lyerly, D., M.D. Roberts, C. Phelps, T.D. Wilkins. 1986. FEMS Microbio. Let. 33:31.
- 26. Taylor, N.S., G.M. Thorne, J.G. Bartlett. 1981. Infect. Immun. 34:1036.
- 27. Florin, L., M. Theslan. 1981. Infect. Immun. 33:66.
- 28. Krivan, H.C., G.F. Clark, D.F. Smith, T.C. Wilkins. 1986. Infect. Immun. 53:573.
- 29. Sullivan, N.M., S. Pellett, T.D. Wilkins. 1982. Infect. Immun. 35:1032.

- 30. Banno, Y., T. Kobayashi, K. Watanabe, K. Ueno, Y. Nozawa. 1981. Biochem.Interm. 6:629.
- 31. Aronsson, B., R. Moliby, C.E. Nord. 1982. Scand. J. Infect. Dis. Suppl. 35:53.
- 32. Muldrow, L.L., G. Ibeanu, N.I. Lee, N.K. Bose, J. Johnson. 1987. FEBS. 213:249.
- 33. Wren, B.W., C.L. Clayton, P.P. Mullariy, S. Tabaqchall. 1988. FEBS. 225:82.
- 34. Price, S.B., C.J. Phelps, T.D. Wilkins, J.L. Johnson. 1987. Curr. Microbiol. 16:55.
- 35. von Eichel-Streiber, C., D. Suckau, M. Wachter, U. Hadding. 1989. J. Gen Microbiol. 135:55.
- 36. Dove, C.H., S.Z. Wang, S.B. Price, C.J. Phelps, D.M. Lyerly, T.D. Wilkins, J.L. Johnson. 1990. Infect. Immun. 58.480.
- 37. Sauerborn, M., C. von Eichel-Streiber. 1990. Nucleic Acids Res. 18:1629.
- 38. McMillin, D.E., L. Muldrow, S.J. Leggette, Y. Abdulahi, and U.M. Ekanemesang. Submitted to FEBS., 1990.
- 39. Jameson, B.A., and Wolf, H. (1988) CABIOS. 4,181.
- 40. Young, R.A., R.W. Davis. 1983. Proc. Natl. Acad. Sci. USA 80:1194.
- 41. Wren, B.W., C.L. Clayton, N.B. Castledine, S. Tabaqchali. 1990. J. Clin. Microbiol. 28:1808.
- 42. Wren, B.W., C.L. Clayton, S. Tabaqchali. 1990. FEMS Microbiol. Lett. 90:1.
- 43. Gross, C.H., G.F. Rohrmann. 1990. BioTechniques. 8:196.
- 44. Henikoff, S. 1987. Methods in Enzymology 155:156

```
THE CCT ANT GCT CCT TEA AGA G 3'
               GGA
                   TTA CGA
                            GGA
                                 AGT
                                     TCT
                220
                    Asn
                       Ala
                            Pro
                                 Ser
                                     Ara
           TTC
               AGA
                    TCA
                            CN
                                 AAT
                                     ac
                                         6 3.
                       77G
                                         CTT AA 5'
               TCT
                   AGT AAC
                                TTA
                            CTT
                                    CTG
                   Ser Glu Asn Asp
                YEG
                                    Gly
                                         6 3'
           11C
               C11
                   GAT TCA
                           ATA
                                 AGA
                                     GAT
             G
               GAA
                   CTA AGT
                           TAT TCT
                                     GTA
                                         CTT AA 5'
                Leu Asp Ser
                           Ile Arg
                                    Asp
           TTC
               CCA GGT TTA AGA
                                 TCA
                                    TTG
                                         GUA ANT GAC GGA ACT AGA
                                         CTT TTA CTG CCT TGA: TCT
               GGT CCA AAT TCT AGT
                                     AAC
                                         Glu Asn Asp Gly Thr Arg
                Pro Gly Leu Arg Ser
                                     Leu
                                         TAC CCA GGT AAA G 3'
           CTT
                   TCA ATA AGA GAT
                                     TAA
               GAT
                                         ATG GGT CCA TTT CTT AA 5'
       AAT
           GAA
               CTA
                   AGT TAT
                            TCT CTA
                                     AAT
       Leu
           Leu
               Asp
                   Ser Ile
                            Arg Asp
                                    Leu
                                         Tyr Pro Gly Lys.
                            GAA AAT
               AGA
                    CCA AGA
                                     GAG
                                           3'
                TCT
                   CGT
                       TCT
                           CTT
                                TTA CTC
                                         GTT AA 5'
                Azq
                   Pro Arg
                           Glu Asn Glu
           TIC AAA
                                         AGA
                   TAT ANA ACT TCA AGC
    3'
             G TTT ATA TTT TGA AGT TCG TCT
               Lsy Try Lsy Thr Ser Ser Arg
               AAT AGA G 3'
               TTA
                   TCT CTT AA 5'
               Aso
                    Arg
           TTC TCT
                    AAT
                       CTA ANA ANA GAT G 3'
              AGA
                    TTA GAT
                           TTT TTT CTA CTT AA 5'
               Ser
                       Leu Lys Lys Asp
                    Asp
                           ACT TCA AGC AGA AAT AGA GCA CTC
           TTC
               XXX
                    TAT AAA
             G TTT
                    ATA TTT
                            TGA AGT TCG TCT TTA TCT CGT GAG AGA
               Lys
                    Tyr Lys
                            Thr Ser
                                     Ser Arc Asn Arg Ala Leu Ser
                                     G 3'
               AAT
                    CTA
                       AAA
                            AAA GAT
               TTA
                    GAT
                        777
                            TTT CTA
                                     CTT AA 5'
               Asn
                    Leu
                       Lsy
                            Lsy
                                Asp
  5' AA 27C
              AGG
                    ATA
                        CCI
                            CAY
                                AGA TTA ANA ANT
               100
                    TAT
                        GGA
                            CTT TCT AAT TTT TTA
                            Glu Arg Leu Lys Asn
               Arq
                    Ile Pro
           AAG
               GAA
                    AAA GTA
                            AAA G
                                     3,
                                CTT AA 5'
           TTC
               CTT
                   TTT CAT
                            777
                        Val
           Lys
               Glu
                   Lys
                            Lys
10. 5' AA
           TTC
               CGA
                   ACT
                       ATT
                            GAT
                                GGT ANA ANA TAT G
           GCT
               TGA
                   TAA
                       CTA
                            CCA TIT TIT ATA CTI AA 5'
           Ara
               Thr
                   Ile
                            Gly Lys Lys Tyr
                       Asp
11. 5'
           TTC
               GAT
                   GC7
                       AAT
                            AAT GAA TCT AAA G 3'
               CTA
                   CGA
                       TTA
                            TTA CTT AGG TTT CTT AA 5'
               CEÁ
                   Ala
                       nek
                            Asn Glu Ser Lys
12. 5'
           TTC
              GAT
                   GCT
                       AAC
                           AAT ATA GAA G
   3'
            G CTA
                  CGA TTG TIA TAT CTT CTT AA 5'
               Asp
                  Ala Asn Asn Ile Glu
```

Figure 1. Epitopes Predicated for the 300 bp of Toxin A Gene.






Figure 2. Southern hybridization of restriction digested C. difficile chromosomal DNA with [alpha-32P] dCTP labeled lambda cd19. C. difficile chromosomal DNA was digested with Taq1, lane 1; HindIII, lane 2; and Pst1, lane 3.




Figure 3. Toxin A DNA inserts digested from BlueScript hybrids. An 800 bp fragment was amplified from <u>C. difficile</u> strain 10463, and cloned into the <u>Not</u>l site of BlueScript. The five bands represent 300 bp fragments that were digested from five different hybrid BlueScript clones.

DISTRIBUTION LIST

1 Copy Commander

US Army Medical Research and Development Command

ATTN: SGRD-RMI-S

Fort Detrick

Frederick, Maryland 21702-5012

Defense Technical Information Center (DTIC) ATTN: DTIC-DDAC 2 copies

Cameron Station

Alexandria, Virginia 22304-6145

1 сору Dean

School of Medicine

Uniformed Services University of the Health Sciences

4301 Jones Bridge Road

Bethesda, Maryland 20814-4799

Commandant 1 сору

Academy of Health Sciences, US Army

ATTN: ASH-CDM

Fort Sam Houston, Texas 78234-6100

4 copies Commander

US Army Medical Material Development Command ATTN: SGRD-UMS/B

Fort Detrick

Frederick, Maryland 21702-5009